Merck KGaA's Cladribine Revival Smacks Of Desperation

In a surprise development, Merck KGaA has decided to file for approval of cladribine, the oral multiple sclerosis medicine it suspended in late-stage trials more than four years ago. It now says that, having evaluated new data and done additional analyses of the product's benefit-risk profile, it will file for approval in Europe in the first half of 2016, and that it is developing plans for filings in other markets.